Zentalis Pharmaceuticals’ (ZNTL) Neutral Rating Reiterated at Wedbush

Wedbush restated their neutral rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research report released on Friday,Benzinga reports. They currently have a $4.00 price objective on the stock.

ZNTL has been the topic of several other research reports. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday. UBS Group lowered their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, Wells Fargo & Company cut their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $8.24.

Zentalis Pharmaceuticals Stock Up 1.1 %

ZNTL opened at $1.81 on Friday. The stock’s 50 day moving average price is $2.04 and its two-hundred day moving average price is $2.85. The firm has a market capitalization of $129.98 million, a P/E ratio of -0.73 and a beta of 1.75. Zentalis Pharmaceuticals has a 12-month low of $1.61 and a 12-month high of $16.27.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Wednesday, March 26th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.09. The business had revenue of $26.90 million during the quarter. As a group, analysts anticipate that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current year.

Insider Activity

In related news, Director Jan Skvarka acquired 60,000 shares of the business’s stock in a transaction on Friday, January 31st. The stock was bought at an average cost of $1.72 per share, with a total value of $103,200.00. Following the completion of the acquisition, the director now owns 149,551 shares in the company, valued at $257,227.72. The trade was a 67.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Ingmar Bruns bought 20,000 shares of the stock in a transaction dated Thursday, February 6th. The stock was purchased at an average cost of $2.28 per share, for a total transaction of $45,600.00. Following the acquisition, the insider now owns 36,629 shares in the company, valued at $83,514.12. The trade was a 120.27 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company’s stock.

Institutional Trading of Zentalis Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Barclays PLC raised its holdings in shares of Zentalis Pharmaceuticals by 18.5% in the third quarter. Barclays PLC now owns 75,395 shares of the company’s stock valued at $277,000 after buying an additional 11,748 shares during the last quarter. Verition Fund Management LLC raised its stake in shares of Zentalis Pharmaceuticals by 172.1% in the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after acquiring an additional 951,500 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Zentalis Pharmaceuticals by 115.6% in the fourth quarter. SG Americas Securities LLC now owns 56,389 shares of the company’s stock worth $171,000 after acquiring an additional 30,240 shares during the last quarter. Savant Capital LLC acquired a new position in shares of Zentalis Pharmaceuticals during the fourth quarter worth approximately $72,000. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Zentalis Pharmaceuticals by 22.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company’s stock valued at $1,507,000 after purchasing an additional 91,152 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.